Boan Biotech’s New ADCC-Enhanced Anti-Claudin 18.2 Antibody Drug BA1105 Approved for Clin...

For treating Claudin18.2-positive advanced solid tumors.

Luye Pharma’s Class 1 New Drug LY03015 Soon to Begin Clinical Trials in China The drug is...

LY03015 is used for the treatment of Tardive Dyskinesia and Huntington's Disease.

Research Results of Luye Pharma’s Next-Generation VMAT2 Inhibitor LY03015 Published in Eu...

The results demonstrate LY03015’s high binding affinity for VMAT2 and excellent inhibition of DA uptake, indi...

Boan Biotech’s Dulaglutide Injection (BA5101) Approved for Clinical Trials in China

For glycemic control in adult patients with type 2 diabetes.

Boan Biotech to Present the Pre-clinical Data of Its Proprietary CD3+ T-cell Engager Platf...

Luye Pharma’s Rivastigmine Multi-Day Transdermal Patch Receives Marketing Approval in the...

For the treatment of mild to moderate dementia associated with Alzheimer’s disease